Gene therapy · Antagonist of interleukin-1 receptor (IL1R1) · developed by Pacira Pharmaceuticals
Enekinragene Inzadenovec is a gene therapy that delivers an interleukin-1 receptor antagonist (IL-1Ra) gene, administered by intra-articular injection. It is being studied for the treatment of knee osteoarthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06884865 | Phase 2 | Osteoarthritis (OA) of the Knee | Recruiting | PCRX |
| NCT04119687 | Phase 1 | Osteoarthritis, Knee | Active not recruiting | PCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Osteoarthritis (OA) of the KneeOsteoarthritis, Knee
Updated Oct 25, 2026. Something wrong or missing? Report it on the PCRX page.
See PCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PCRX catalysts and pipeline →